Article
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
Cancer discovery - 1 Jun 2015
Dienstmann Rodrigo, Patnaik Amita, Garcia-Carbonero Rocio, Cervantes Andrés, Benavent Marta, Roselló Susana, Tops Bastiaan B J, van der Post Rachel S, Argilés Guillem, Skartved Niels J Ø, Hansen Ulla H, Hald Rikke, Pedersen Mikkel W, Kragh Michael, Horak Ivan D, Braun Stephan, Van Cutsem Eric, Tolcher Anthony W, Tabernero Josep
Abstract excerpt
UNLABELLED: Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.